Complications from Stereotactic Body Radiotherapy for Lung Cancer
1
School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
2
Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
3
Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Academic Editor: Siow Ming Lee
Cancers 2015, 7(2), 981-1004; https://doi.org/10.3390/cancers7020820
Received: 28 February 2015 / Accepted: 8 June 2015 / Published: 15 June 2015
(This article belongs to the Special Issue Non-Small Cell Lung Cancer Therapies)
Abstract
Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early stage, node negative non-small cell lung cancer (NSCLC) in patients who are either medically inoperable or refuse surgical resection. SBRT has high local control rates and a favorable toxicity profile relative to other surgical and non-surgical approaches. Given the excellent tumor control rates and increasing utilization of SBRT, recent efforts have focused on limiting toxicity while expanding treatment to increasingly complex patients. We review toxicities from SBRT for lung cancer, including central airway, esophageal, vascular (e.g., aorta), lung parenchyma (e.g., radiation pneumonitis), and chest wall toxicities, as well as radiation-induced neuropathies (e.g., brachial plexus, vagus nerve and recurrent laryngeal nerve). We summarize patient-related, tumor-related, dosimetric characteristics of these toxicities, review published dose constraints, and propose strategies to reduce such complications. View Full-TextKeywords:
stereotactic body radiation therapy (SBRT); stereotactic ablative radiotherapy (SABR); non-small cell lung cancer (NSCLC); toxicity; complications
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Kang, K.H.; Okoye, C.C.; Patel, R.B.; Siva, S.; Biswas, T.; Ellis, R.J.; Yao, M.; Machtay, M.; Lo, S.S. Complications from Stereotactic Body Radiotherapy for Lung Cancer. Cancers 2015, 7, 981-1004.